Leading the way
in PD-L1 testing
Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).
Results you can trust
The first and only FDA-approved and
CE-IVD marked PD-L1 test for use in both
non-squamous NSCLC and melanoma.
Making an impact means changing lives
Demand precision - Push the boundaries of what's possible today with exceptional quality pathology solutions.
See our solutions within pathology, next generation sequencing and molecular cancer research.
2016 Product Catalog
The 2016 Pathology Product Catalog is now available for download.
Events and Congresses
Meet us at congresses and events around the world.